Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Integrated Biological Markers for the Prediction of Treatment Response in Depression: A Pilot Study

Trial Profile

Integrated Biological Markers for the Prediction of Treatment Response in Depression: A Pilot Study

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Escitalopram (Primary) ; Aripiprazole
  • Indications Major depressive disorder
  • Focus Biomarker; Therapeutic Use
  • Acronyms CAN-BIND-1
  • Most Recent Events

    • 20 Dec 2023 Results assessing SGK1 mRNA expression from peripheral blood, and left and right hippocampal volume at baseline, as well as change in these markers over the first 8 weeks of a 16-week open-label trial of escitalopram as part of the Canadian Biomarker Integration Network in Depression program (MDD [n = 161] and healthy [n = 91] comparison participants, published in the European Neuropsychopharmacology.
    • 15 Nov 2023 Results published in the Journal of Clinical Psychiatry
    • 01 May 2022 Results assessing relationships between antidepressant treatment outcomes and sexual functioning published in the Journal of Psychopharmacology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top